PMC:7318948 / 13251-13838 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T199","span":{"begin":70,"end":74},"obj":"PR:000001393"},{"id":"T200","span":{"begin":209,"end":213},"obj":"PR:000001393"},{"id":"T201","span":{"begin":224,"end":232},"obj":"SP_7"},{"id":"T202","span":{"begin":314,"end":318},"obj":"PR:000001393"},{"id":"T203","span":{"begin":442,"end":446},"obj":"PR:000001393"},{"id":"T204","span":{"begin":457,"end":465},"obj":"SP_7"},{"id":"T205","span":{"begin":486,"end":491},"obj":"UBERON:0000062"},{"id":"T74114","span":{"begin":70,"end":74},"obj":"PR:000001393"},{"id":"T60722","span":{"begin":209,"end":213},"obj":"PR:000001393"},{"id":"T56397","span":{"begin":224,"end":232},"obj":"SP_7"},{"id":"T49424","span":{"begin":314,"end":318},"obj":"PR:000001393"},{"id":"T23213","span":{"begin":442,"end":446},"obj":"PR:000001393"},{"id":"T7988","span":{"begin":457,"end":465},"obj":"SP_7"},{"id":"T61629","span":{"begin":486,"end":491},"obj":"UBERON:0000062"}],"text":"Chen et al. found in a sample of 48 patients that increased levels of IL-6 significantly correlated to disease severity [12]. Another study reported a significant association between lymphopenia and increased IL-6 levels in COVID-19 non-survivors compared with survivors. [12,13] These findings suggest monitoring IL-6 levels to evaluate cytokine storm as a prognostic tool [12]. However, it is likely that physicians do not routinely follow IL-6 levels in COVID-19 patients with solid organ transplants, as it was not a commonly reported lab value in the studies we evaluated (Table 2)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T79","span":{"begin":338,"end":346},"obj":"Body_part"},{"id":"T80","span":{"begin":480,"end":491},"obj":"Body_part"}],"attributes":[{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma55670"}],"text":"Chen et al. found in a sample of 48 patients that increased levels of IL-6 significantly correlated to disease severity [12]. Another study reported a significant association between lymphopenia and increased IL-6 levels in COVID-19 non-survivors compared with survivors. [12,13] These findings suggest monitoring IL-6 levels to evaluate cytokine storm as a prognostic tool [12]. However, it is likely that physicians do not routinely follow IL-6 levels in COVID-19 patients with solid organ transplants, as it was not a commonly reported lab value in the studies we evaluated (Table 2)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T49","span":{"begin":486,"end":491},"obj":"Body_part"}],"attributes":[{"id":"A49","pred":"uberon_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"Chen et al. found in a sample of 48 patients that increased levels of IL-6 significantly correlated to disease severity [12]. Another study reported a significant association between lymphopenia and increased IL-6 levels in COVID-19 non-survivors compared with survivors. [12,13] These findings suggest monitoring IL-6 levels to evaluate cytokine storm as a prognostic tool [12]. However, it is likely that physicians do not routinely follow IL-6 levels in COVID-19 patients with solid organ transplants, as it was not a commonly reported lab value in the studies we evaluated (Table 2)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T74","span":{"begin":183,"end":194},"obj":"Disease"},{"id":"T75","span":{"begin":224,"end":232},"obj":"Disease"},{"id":"T76","span":{"begin":457,"end":465},"obj":"Disease"}],"attributes":[{"id":"A74","pred":"mondo_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"},{"id":"A75","pred":"mondo_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Chen et al. found in a sample of 48 patients that increased levels of IL-6 significantly correlated to disease severity [12]. Another study reported a significant association between lymphopenia and increased IL-6 levels in COVID-19 non-survivors compared with survivors. [12,13] These findings suggest monitoring IL-6 levels to evaluate cytokine storm as a prognostic tool [12]. However, it is likely that physicians do not routinely follow IL-6 levels in COVID-19 patients with solid organ transplants, as it was not a commonly reported lab value in the studies we evaluated (Table 2)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T186","span":{"begin":21,"end":22},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T187","span":{"begin":33,"end":35},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T188","span":{"begin":149,"end":150},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T189","span":{"begin":356,"end":357},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T190","span":{"begin":486,"end":491},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T191","span":{"begin":519,"end":520},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Chen et al. found in a sample of 48 patients that increased levels of IL-6 significantly correlated to disease severity [12]. Another study reported a significant association between lymphopenia and increased IL-6 levels in COVID-19 non-survivors compared with survivors. [12,13] These findings suggest monitoring IL-6 levels to evaluate cytokine storm as a prognostic tool [12]. However, it is likely that physicians do not routinely follow IL-6 levels in COVID-19 patients with solid organ transplants, as it was not a commonly reported lab value in the studies we evaluated (Table 2)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T147","span":{"begin":70,"end":72},"obj":"Chemical"},{"id":"T149","span":{"begin":209,"end":211},"obj":"Chemical"},{"id":"T151","span":{"begin":314,"end":316},"obj":"Chemical"},{"id":"T153","span":{"begin":442,"end":444},"obj":"Chemical"}],"attributes":[{"id":"A147","pred":"chebi_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A148","pred":"chebi_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A149","pred":"chebi_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A150","pred":"chebi_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A151","pred":"chebi_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A152","pred":"chebi_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A153","pred":"chebi_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A154","pred":"chebi_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Chen et al. found in a sample of 48 patients that increased levels of IL-6 significantly correlated to disease severity [12]. Another study reported a significant association between lymphopenia and increased IL-6 levels in COVID-19 non-survivors compared with survivors. [12,13] These findings suggest monitoring IL-6 levels to evaluate cytokine storm as a prognostic tool [12]. However, it is likely that physicians do not routinely follow IL-6 levels in COVID-19 patients with solid organ transplants, as it was not a commonly reported lab value in the studies we evaluated (Table 2)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"331","span":{"begin":70,"end":74},"obj":"Gene"},{"id":"332","span":{"begin":209,"end":213},"obj":"Gene"},{"id":"333","span":{"begin":314,"end":318},"obj":"Gene"},{"id":"334","span":{"begin":442,"end":446},"obj":"Gene"},{"id":"335","span":{"begin":36,"end":44},"obj":"Species"},{"id":"336","span":{"begin":466,"end":474},"obj":"Species"},{"id":"337","span":{"begin":183,"end":194},"obj":"Disease"},{"id":"338","span":{"begin":224,"end":232},"obj":"Disease"},{"id":"339","span":{"begin":457,"end":465},"obj":"Disease"}],"attributes":[{"id":"A331","pred":"tao:has_database_id","subj":"331","obj":"Gene:3569"},{"id":"A332","pred":"tao:has_database_id","subj":"332","obj":"Gene:3569"},{"id":"A333","pred":"tao:has_database_id","subj":"333","obj":"Gene:3569"},{"id":"A334","pred":"tao:has_database_id","subj":"334","obj":"Gene:3569"},{"id":"A335","pred":"tao:has_database_id","subj":"335","obj":"Tax:9606"},{"id":"A336","pred":"tao:has_database_id","subj":"336","obj":"Tax:9606"},{"id":"A337","pred":"tao:has_database_id","subj":"337","obj":"MESH:D008231"},{"id":"A338","pred":"tao:has_database_id","subj":"338","obj":"MESH:C000657245"},{"id":"A339","pred":"tao:has_database_id","subj":"339","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Chen et al. found in a sample of 48 patients that increased levels of IL-6 significantly correlated to disease severity [12]. Another study reported a significant association between lymphopenia and increased IL-6 levels in COVID-19 non-survivors compared with survivors. [12,13] These findings suggest monitoring IL-6 levels to evaluate cytokine storm as a prognostic tool [12]. However, it is likely that physicians do not routinely follow IL-6 levels in COVID-19 patients with solid organ transplants, as it was not a commonly reported lab value in the studies we evaluated (Table 2)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T27","span":{"begin":183,"end":194},"obj":"Phenotype"},{"id":"T28","span":{"begin":338,"end":352},"obj":"Phenotype"}],"attributes":[{"id":"A27","pred":"hp_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/HP_0001888"},{"id":"A28","pred":"hp_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":"Chen et al. found in a sample of 48 patients that increased levels of IL-6 significantly correlated to disease severity [12]. Another study reported a significant association between lymphopenia and increased IL-6 levels in COVID-19 non-survivors compared with survivors. [12,13] These findings suggest monitoring IL-6 levels to evaluate cytokine storm as a prognostic tool [12]. However, it is likely that physicians do not routinely follow IL-6 levels in COVID-19 patients with solid organ transplants, as it was not a commonly reported lab value in the studies we evaluated (Table 2)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T125","span":{"begin":0,"end":125},"obj":"Sentence"},{"id":"T126","span":{"begin":126,"end":379},"obj":"Sentence"},{"id":"T127","span":{"begin":380,"end":587},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Chen et al. found in a sample of 48 patients that increased levels of IL-6 significantly correlated to disease severity [12]. Another study reported a significant association between lymphopenia and increased IL-6 levels in COVID-19 non-survivors compared with survivors. [12,13] These findings suggest monitoring IL-6 levels to evaluate cytokine storm as a prognostic tool [12]. However, it is likely that physicians do not routinely follow IL-6 levels in COVID-19 patients with solid organ transplants, as it was not a commonly reported lab value in the studies we evaluated (Table 2)."}